skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Chronopharmacology of L-DOPA: implications for orthochronal therapy in the prevention of circadian dyschronism

Conference ·
OSTI ID:6845361

Two experimental results showed a significant influence of the circadian phase time-of-administration of L-DOPA upon the circadian rhythm of the rat, as judged by measures of core temperature. It is concluded that, in order to minimize the deleterious side effects and maximize the beneficial effects of a drug such as L-DOPA, orthochronal therapy is indicated. How orthochronal is to be defined when extrapolated to organisms apparently deficient in either tyrosine hydroxylase or in L-DOPA itself (as in the case of Parkinson's disease) will require experimental trial with appropriate subjects.

Research Organization:
Argonne National Lab., Ill. (USA)
DOE Contract Number:
W-31-109-ENG-38
OSTI ID:
6845361
Report Number(s):
CONF-780234-1
Resource Relation:
Conference: Symposium on clinical chronopharmacy, chronotherapeutics, chronopharmacology, Tallahassee, FL, USA, 10 Feb 1978
Country of Publication:
United States
Language:
English